Every cough you have ever produced was mediated by the vagus nerve. The vagus carries the sensory signals that detect irritants in the airways, relays them to the brainstem cough centre, and carries the motor commands back to the larynx and diaphragm that produce the explosive expulsion of air. When this system malfunctions — when vagal afferents become sensitised or damaged — the result can be a chronic, debilitating cough that persists for months or years without an obvious cause. Understanding the vagal cough pathway explains both why coughing exists and why it sometimes goes wrong.
The Vagal Cough Reflex Arc
The cough reflex is a five-stage arc, and the vagus nerve is involved in four of them. Vagal afferent fibres in the airway mucosa detect mechanical or chemical irritants. These fibres include rapidly adapting receptors (RARs), which respond to mechanical deformation such as inhaled particles or mucus, C-fibres, which are unmyelinated nerve endings that express chemosensitive ion channels including TRPV1 (the capsaicin receptor) and TRPA1 (activated by irritants like acrolein, allyl isothiocyanate, and cigarette smoke), and slowly adapting stretch receptors (SARs), which primarily regulate breathing rhythm but modulate cough threshold.
These afferent signals travel via the vagus nerve (specifically the superior laryngeal nerve for the larynx and pharynx, and the recurrent laryngeal nerve and pulmonary branches for the lower airways) to the nucleus tractus solitarius (NTS) in the medulla. The NTS integrates these signals and communicates with the cough pattern generator — a network involving the ventral respiratory group and the nucleus ambiguus.
Motor output then travels back via the vagus: the recurrent laryngeal nerve controls the vocal cords (adducting them during the compressive phase, then abducting them during the expulsive phase), while the phrenic nerve (C3–C5, not vagal) drives the diaphragmatic contraction that generates the high intrathoracic pressure necessary for effective cough. The result is a coordinated sequence: deep inspiration, glottic closure, abdominal and thoracic muscle contraction building pressure to 300 mmHg or more, followed by sudden glottic opening and airflow at speeds approaching 500 miles per hour.
Arnold’s Ear-Cough Reflex
One of the most striking demonstrations of vagal cough physiology is Arnold’s ear-cough reflex. Arnold’s nerve — the auricular branch of the vagus — innervates the external ear canal, cymba conchae, and tragus. In 2–4% of the population, stimulation of this nerve (by cotton swabs, hearing aids, earwax removal, or even cold water in the ear canal) triggers a cough. This happens because Arnold’s nerve afferents project to the same NTS neurons that receive airway cough afferents — the brainstem cannot distinguish between a stimulus in the ear and a stimulus in the throat.
Arnold’s reflex has clinical importance beyond curiosity. It is the anatomical basis for transcutaneous auricular vagus nerve stimulation (taVNS), which targets Arnold’s nerve at the cymba conchae to activate NTS projections for therapeutic purposes. It also explains why some patients develop chronic cough after ear procedures or hearing aid fitting — the sustained stimulation of Arnold’s nerve maintains a low-level cough drive.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Breathwork
- HRV biofeedback
- Polyvagal-informed therapy
- Somatic therapy
- Craniosacral therapy
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Vagal Neuropathic Cough
Vagal neuropathic cough (VNC) is a chronic cough caused by injury or sensitisation of vagal afferent nerves, analogous to how neuropathic pain results from injury to somatic sensory nerves. Patients with VNC develop a hypersensitive cough reflex: they cough in response to stimuli that would not trigger coughing in healthy people — talking, laughing, cold air, strong scents, changes in air temperature, or even swallowing.
The concept of cough hypersensitivity syndrome, formalised by the European Respiratory Society in 2014, provides a framework for understanding VNC. Central sensitisation occurs when repeated vagal afferent stimulation (from infections, reflux, or inflammation) causes neuroplastic changes in the NTS and higher brainstem centres, lowering the cough threshold. Peripheral sensitisation involves upregulation of TRPV1 and TRPA1 channels on vagal C-fibre endings in the airway mucosa, making them fire at lower stimulus thresholds. Allotussia — coughing in response to normally innocuous stimuli — is the cough equivalent of allodynia in pain medicine.
Common triggers for vagal neuropathic cough include post-viral vagal neuritis (upper respiratory infections, especially those caused by viruses with neurotropic properties, can inflame and damage vagal fibres — this mechanism gained prominence during the COVID-19 pandemic, as post-COVID chronic cough became a widely recognised sequela), chronic laryngopharyngeal reflux (acid and pepsin exposure sensitises vagal afferents in the larynx and pharynx), and direct vagal injury from surgery, intubation, or cervical spine procedures. The cervicovagopathy framework (Hauser et al. 2025) suggests that physical insults to the cervical vagus can produce vagal neuropathic cough as part of a broader syndrome of vagal dysfunction.
Laryngeal Hypersensitivity Syndrome
Vagal neuropathic cough is increasingly understood as one manifestation of a broader condition: laryngeal hypersensitivity syndrome. This umbrella term, proposed by Morrison and colleagues, encompasses chronic cough, paradoxical vocal fold movement (vocal cord dysfunction), muscle tension dysphonia, and globus pharyngeus (the sensation of a lump in the throat) — all of which involve abnormal sensory processing in the vagal territory of the larynx and pharynx.
Patients with laryngeal hypersensitivity often experience several of these symptoms simultaneously or sequentially: cough, throat clearing, voice changes, throat tightness, and exercise-induced laryngeal obstruction. The common thread is sensitisation of the superior laryngeal nerve — a vagal branch carrying sensory fibres from the laryngeal mucosa — and altered central processing in the NTS.
Diagnosis of Vagal Cough Disorders
Chronic cough (lasting more than eight weeks) warrants systematic evaluation. The standard approach addresses the three most common causes first: upper airway cough syndrome (post-nasal drip), asthma or eosinophilic airway inflammation, and gastro-oesophageal reflux disease. When these are excluded or adequately treated and the cough persists — chronic refractory cough — vagal neuropathic cough becomes a primary consideration.
Laryngoscopy (flexible nasendoscopy) can reveal signs of vagal laryngeal involvement: vocal cord paresis, arytenoid erythema or oedema, paradoxical vocal fold movement, or a hypersensitive laryngeal adductor reflex. Cough reflex sensitivity testing using inhaled capsaicin (which activates TRPV1 on vagal C-fibres) can quantify the threshold at which coughing is triggered — patients with VNC characteristically cough at much lower capsaicin concentrations than healthy controls.
The recently developed REVA 3D vagus nerve atlas (Feinstein lab, July 2026) may eventually improve diagnostic precision by allowing clinicians to identify specific points of vagal compromise along the nerve’s pathway, though clinical application of this atlas for cough diagnosis is still in early stages.
Treatment Approaches
Neuromodulator medications form the pharmacological backbone of VNC treatment. Gabapentin, at doses of 300–1800 mg daily, has the strongest evidence — a 2012 randomised controlled trial by Ryan and colleagues demonstrated significant cough reduction compared to placebo in patients with chronic refractory cough, with improvements in cough severity, cough frequency, and cough-specific quality of life. Pregabalin and low-dose amitriptyline (10–50 mg at bedtime) are alternatives that target similar neuropathic mechanisms through different pharmacological pathways.
Speech pathology-based cough suppression therapy is the other pillar of treatment. This approach, developed by programs at tertiary cough clinics, teaches patients to identify their cough urge, apply cough suppression techniques (swallowing, sipping water, controlled breathing), reduce laryngeal tension through vocal hygiene, and desensitise the cough reflex through graded exposure to triggers. Randomised trials have shown that speech pathology therapy is as effective as gabapentin and that the combination may be more effective than either alone.
P2X3 receptor antagonists represent a newer pharmacological approach. Gefapixant (developed by Merck) targets purinergic P2X3 receptors on vagal afferent nerve endings in the airway — these receptors respond to ATP released by damaged epithelial cells, triggering the cough reflex. Clinical trials have demonstrated significant cough reduction, though the main side effect (taste alteration or loss, dysgeusia) has limited its clinical uptake. Several next-generation P2X3 antagonists with improved selectivity are in clinical development.
Vagus nerve stimulation itself — paradoxically — is being investigated for chronic cough. The rationale is that controlled, regular vagal stimulation may desensitise the hyperactive cough reflex through habituation, similar to how transcutaneous electrical nerve stimulation can reduce chronic pain. Early-phase clinical trials of taVNS for chronic cough have reported promising results, though this application remains experimental.
The vagus nerve is the master controller of the cough reflex — and understanding its role opens the door to more effective treatment of chronic cough conditions. Get My Vagus Nerve & Me eBook for a complete, research-backed guide to how your vagus nerve works and what happens when its signalling goes wrong.
